Patient Registry of Roflumilast In Real Life
Phase of Trial: Phase IV
Latest Information Update: 13 Sep 2017
Price : $35 *
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 05 Dec 2016 Status changed from active, no longer recruiting to completed.
- 15 Jan 2016 Planned End Date changed from 1 Jan 2016 to 1 Apr 2016 as per ClinicalTrials.gov record.